Nodus Oncology Secures £2.4m ($2.9m) Investment
February 07, 2023 02:00 ET
|
Nodus Oncology
Nodus Oncology Secures £2.4m ($2.9m) Investment KHAN Technology Transfer Fund I (KHAN-I) have invested alongside existing investor Cumulus Oncology Bert Klebl, Managing Director of KHAN-I will join...
Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programme
September 08, 2022 01:15 ET
|
Nodus Oncology
Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programme Acquisition enables Nodus Oncology to continue building its portfolio of first and best-in-class molecules...
Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets
September 06, 2022 02:00 ET
|
Nodus Oncology
Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response...